HIV and pregnancy;VIH et grossesse

Pathologie Biologie

Volumn 50, Issue 9, 2002, Pages 576-579

  Rouzioux, C ^a   Chaix, M L ^a   Burgard, M ^a   Mandelbrot, L ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CHU Hop Cochin Port Royal/B C B ^*  (France)

Author keywords

HIV; Mother to child transmission; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

CONFERENCE PAPER; ENDEMIC DISEASE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; PATHOPHYSIOLOGY; PREGNANCY; SIDE EFFECT; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0036858639     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(02)00353-X     Document Type: Conference Paper

References (8)

1. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type I transmission by use of a Markov model. Am J Epidemiol 1995;142:1330-7.
2. European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in prevention of vertical VIH-1 transmission: A randomised clinical trial. Lancet 1999;353:1035-9.
3. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal VIH-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.
4. Connor EM, Sperling RS, Gelber, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
5. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child VIH-1 transmission in France. J Pediatr 1997;131:857-62.
6. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochodrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-99.
7. Delfraissy JF, pour les groupes d'experts cliniciens et virologues. Stratégies d'Utilisation des Antirétroviraux dans l'Infection par le VIH. Paris: Flammarion 1999:143-60.
8. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du Groupe d'Experts. Paris: Flammarion, Rapport; 2000.